Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia​

Braun TP, Coblentz C, Smith BM,  Coleman DJ,  Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE. PNAS 2020.

 Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia​

Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B,  Garcia B, LaTocha D, Weeder BR, Grzadkowski MR,  Estabrook JC,  Manning HG, Watanabe-Smith K, Jeng S, Smith JL, Leonti AR, Ries RE,  McWeeney S,  GenuaCD, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ and Maxson JE. Nature Communications. 2019.

A novel germline variant in CSF3R reduces N-glycosylation and exerts potent oncogenic effects in leukemia

Spiciarich DR,  Oh ST,  Foley A,  Hughes SB, Mauro MJ,  Abdel-Wahab O, Press RD, Viner R,  Thompson SL, Chen Q, Azadi P, Bertozzi CR and Maxson JE. Cancer Research. 2018.

​Genomics of Chronic Neutrophilic Leukemia

Maxson JE, Tyner JW. Blood. 2017 Feb; 129(6):715-722.

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.

Maxson JE, Ries R, Wang Y-C, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong S, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, and Meshinchi S. Blood. 2016 Jun 16;127(24):3094-8.

Identification and characterization of Tyrosine Kinase Non-receptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis

Maxson JE, Abel ML, Wang J, Xianming D, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes S, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, Gray NS, Druker BJ, and Tyner JW. Cancer Res. 2016 Jan 1;76(1):127-38.

The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic and mimics T618I

Maxson JE, Luty SB, MacManiman JD, Paik J, Gotlib JR, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide, CA, Loriaux MM, Stevens EA and Tyner JW. Clinical Cancer Research. 2016 Feb 1;22(3)757-64.

Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series

Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee C-K, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, and Pollyea DA.  Leukemia and Lymphoma. 2016;57(4):927-34.

Therapeutically-targetable ALK point mutations in leukemia

Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Druker BJ and Tyner JW. Cancer Research. Jun 1, 2015; 75(11):2146-50.

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome

Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE and Traer E. Leukemia Research Reports. 2015; 4(1):8-11.

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

Dao KT, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Leukemia Research Reports. 2014 Aug 1;3(2)67-9.

Ligand-independence of the colony stimulating factor 3 receptor (CSF3R) T618I mutation results from loss of O-linked glycosylation and increased receptor dimerization

Maxson JE, Luty SB, Abel ML, Druker BJ, Tyner JW.  Journal of Biological Chemistry. 2014 Feb 28;289(9):5820-7

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

Fleischman AG*, Maxson JE*, Luty SB, Agarwal A, Royer LR, Abel ML, Macmaniman JD, Loriaux MM, Druker BJ, Tyner JW. Blood. 2013 Sept 30.

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia

Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, and Tefferi A. Leukemia. 2013 Sept 27; (9):1870-3.

The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment

Gotlib J, Maxson JE, George TI, and Tyner JW. Blood. 2013 Sep 5; 122(10):1707-11.​

Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML

Maxson JE, Jason Gotlib JR, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney S, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. The New England Journal of Medicine. 2013 May 9;368(19):1781-90.